Rifaximin-ciprofloxacin combination therapy is effective in chronic active refractory pouchitis

Colorectal Disease

Volumn 7, Issue 2, 2005, Pages 182-186

  Abdelrazeq, Ayman S ^a,c   Kelly, S M ^a   Lund, J N ^b   Leveson, S H ^a  

^a YORK HOSPITAL   (United Kingdom)

^b DERBY CITY GENERAL HOSPITAL   (United Kingdom)

^c NONE   (United Kingdom)

Author keywords

Ciprofloxacin; Pouchitis; Rifaximin

Indexed keywords

CIPROFLOXACIN; METRONIDAZOLE; RIFAXIMIN; SALAZOSULFAPYRIDINE;

ADULT; ARTICLE; CLINICAL ARTICLE; DISEASE ACTIVITY; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FOLLOW UP; HISTOPATHOLOGY; HUMAN; ILEITIS; INTESTINE ENDOSCOPY; MEDICAL ASSESSMENT; PATIENT COMPLIANCE; PATIENT MONITORING; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECURRENT DISEASE; REMISSION; SCORING SYSTEM; SIDE EFFECT; TREATMENT OUTCOME; WILCOXON SIGNED RANKS TEST;

ADULT; ANTI-INFECTIVE AGENTS; CHRONIC DISEASE; CIPROFLOXACIN; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; POUCHITIS; RIFAMYCINS; STATISTICS, NONPARAMETRIC; TREATMENT OUTCOME;

EID: 14844347282     PISSN: 14628910     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1463-1318.2004.00746.x     Document Type: Article

References (26)

1. Parks AG, Nicholls RJ, Belliveau P. Proctocolectomy with ileal reservoir and anal anastomosis. Br J Surg 1980; 67: 533-8.
2. Pemberton JH, Kelly KA, Beart RW, Dozois RF, Wolff BG, Ilstrup DM. Ileal pouch-anal anastomosis for chronic ulcerative colitis: Long-term results. Ann Surg 1987; 206: 504-13.
3. Di Febo G, Miglioli M, Lauri A et al. Endoscopic assessment of acute inflammation of the ileal reservoir after restorative ileo-anal anastomosis. Gastrointest Endosc 1990; 36: 6-9.
4. Shepherd NA, Jass JR, Duval I, Moskowitz RL, Nicholls RJ, Morson BC. Restorative proctocolectomy with ileal reservoir: pathological and histochemical study of mucosal biopsy specimens. J Clin Pathol 1987; 40: 601-7.
5. Mahadevan UMA, Sandborn WJ. Diagnosis and management of pouchitis. Gastroenterology 2003; 124: 1636-50.
6. Dozois RR, Cohen Z, Goldberg SM et al. Symposium: restorative proctocolectomy with ileal reservoir. Int J Colorectal Dis 1986; 1: 2-19.
7. Simchuk EJ, Thirlby RC. Risk factors and true incidence of pouchitis in patients after ileal pouch-anal anastomosis. World J Surg 2000; 24: 851-6.
8. Madden MV, McIntyre AS, Nicholls RJ. Double-blind crossover trial of metronidazole versus placebo in chronic unremitting pouchitis. Dig Dis Sci 1994; 39: 1193-6.
9. Shen B, Achkar JP, Lashner BA et al. A randomized clinical trial of ciprofloxacin and metronidazole to treat acute pouchitis. Inflamm Bowel Dis 2001; 7: 301-5.
10. Hurst RD, Molinari M, Chung TP, Rubin M, Michelassi F. Prospective study of the incidence, timing, and treatment of pouchitis in 104 consecutive patients after restorative proctocolectomy. Arch Surg 1996; 131: 497-502.
11. Becker J, Stucchi A, Bryant D. How do you treat refractory pouchitis and when do you decide to remove the pouch? Inflamm Bowel Dis 1998; 4: 167-71.
12. Yli-Kerttula T, Luukkainen R, Yli-Kerttula U et al. Effect of a three month course of ciprofloxacin on the outcome of reactive arthritis. Ann Rheumatic Dis 2000; 59: 565-70.
13. Hoover WW, Gerlach EH, Hoban DJ, Eliopoulos GM, Pfaller MA, Jones RA. Antimicrobial activity and spectrum of rifaximin, a new topical rifamycin derivative. Diagn Microbiol Infect Dis 1993; 16: 111-8.
14. Gillis JC, Borgden RN. Rifaximin: a review of its antibacterial activity, pharmacokinetic and therapeutic potential in conditions mediated by gastrointestinal bacteria. Drugs 1995; 49: 467-84.
15. Gionchetti P, Rizello F, Ferrieri A et al. Rifaximin in patients with moderate or severe ulcerative colitis refractory to steroid treatment: a double-blind, placebo- controlled trial. Dig Dis Sci 1999; 44: 1220-1.
16. Steffen B, Sack DA, Riopel L et al. Therapy of travellers diarrhoea with rifaximin on various continents. Am J Gastroenterol 2003; 98: 1073-8.
17. Di Stefano M, Malservisi S, Vento G, Ferrieri A, Corazza GR. Rifaximin versus chlortetracycline in the short - term treatment of small intestinal bacterial overgrowth. Aliment Pharmacol Ther 2000; 14: 551-6.
18. Williams R, James OF, Warnes TW, Morgan MY. Evaluation of the efficacy and safety of rifaximin in treatment of hepatic encephalopathy: a double-blind, randomized, dose-finding multi-centre study. Eur J Gastroenterol Hepatol 2000; 12: 203-8.
19. Descombe JJ, Dubourg D, Picard M, Palazzini E. Pharmacokinetic study of rifaximin after oral administration in healthy volunteers. Int J Clin Pharm Res 1994; 14: 51-6.
20. Rizzelo F, Gionchetti P, Venturi A et al. Rifaximin systemic absorption in patients with ulcerative colitis. Eur J Clinic Pharmacol 1998; 54: 91-3.
21. Gionchetti P, Rizzello F, Venturi A et al. Antibiotic combination therapy in patients with chronic treatment-resistant pouchitis. Aliment Pharmacol Ther 1999; 13: 713-8.
22. Sandborn WJ, Tremaine WJ, Batts KP, Pemperton JH, Phillips SF. Pouchitis following ileal pouch-anal anastomosis: a pouchitis disease activity index. Mayo Clin Proc 1994; 69: 409-15.
23. Fiorucci S, Distrutti E, Mencarelli A, Barbanti M, Palazzini E, Morelli A. Inhibition of intestinal bacterial translocation with rifaximin modulates lamina propria monocytic cells reactivity and protects against inflammation in a rodent model of colitis. Digestion 2002; 66: 246-5.
24. Svaninger G, Nordgren S, Oresland T, Hulten L. Incidence and characteristics of pouchitis in the Kock continent ileostomy and the pelvic pouch. Scand J Gastroenterol 1993; 28: 695-700.
25. Munoz-Juarez M, Pemberton JH, Sandborn WJ, Tremaine WJ, Dozois RR. Misdiagnosis of specific cytomegalovirus infection of the ileoanal pouch as refractory idiopathic chronic pouchitis: report of two cases. Dis Colon Rectum 1999; 42: 117-20.
26. Mann SD, Pitt J, Springall RG, Thillainayagam AV. Clostridium difficile infection-an unusual cause of refractory pouchitis: report of a case. Dis Colon Rectum 2003; 46: 267-70.